79 related articles for article (PubMed ID: 608542)
21. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
[TBL] [Abstract][Full Text] [Related]
22. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.
Minton JP; Rossio JL; Dixon B; Dodd MC
Clin Exp Immunol; 1976 Jun; 24(3):441-7. PubMed ID: 1084821
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience in the use of C. parvum in the treatment of locally advanced carcinoma of the breast.
Chare MJ; Webster DJ; Baum M
Dev Biol Stand; 1977 Apr 13-15; 38():495-9. PubMed ID: 344104
[TBL] [Abstract][Full Text] [Related]
24. Intralesional injection of BCG using the fibreoptic bronchoscope in the treatment of bronchogenic carcinoma.
Millar JW; Hunter AM; Wightman AJ; Horne NW
Eur J Respir Dis; 1980 Jun; 61(3):162-6. PubMed ID: 7439279
[TBL] [Abstract][Full Text] [Related]
25. Corynebacterium parvum antibodies in healthy and cancer patients.
Hardas U; Jalgaonkar SV; Chatterjee AK
Indian J Cancer; 1982; 19(2):113-5. PubMed ID: 7129515
[No Abstract] [Full Text] [Related]
26. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
[TBL] [Abstract][Full Text] [Related]
27. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study.
Yadeau R; Bates HA; Fortuny I
Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003
[No Abstract] [Full Text] [Related]
28. C1q binding activity in the sera of patients with chronic lung diseases.
Cooper KM; Moore M; Hilton AM
Clin Exp Immunol; 1981 Jul; 45(1):18-28. PubMed ID: 6975678
[TBL] [Abstract][Full Text] [Related]
29. First impressions of I.V. C. parvum in patients with solid tumours.
Günther U; Hoefer-Janker H; Scheef W
Dev Biol Stand; 1977 Apr 13-15; 38():507-8. PubMed ID: 608543
[TBL] [Abstract][Full Text] [Related]
30. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
Lichtenstein AK; Berek J; Kahle J; Zighelboim J
Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
[TBL] [Abstract][Full Text] [Related]
31. Aspects of the immunologic treatment of lung cancer.
Alth G; Denck H; Fischer M; Karrer K; Kokron O; Korizek E; Micksche M; Ogris E; Reider C; Titscher R; Wrba H
Cancer Chemother Rep 3; 1973 Mar; 4(2):271-4. PubMed ID: 4729328
[No Abstract] [Full Text] [Related]
32. [Comparison of two nonspecific immune stimuli in antiblastic chemotherapy].
Bianucci P; Pastorino G
Arch Sci Med (Torino); 1980; 137(1):33-40. PubMed ID: 7458652
[TBL] [Abstract][Full Text] [Related]
33. [The immunostate and immunotherapy of primary bronchogenic carcinoma (author's transl)].
Deng WW
Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1979; 2(1):56-8. PubMed ID: 551912
[No Abstract] [Full Text] [Related]
34. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Gusdon JP; Homesley HD; Jobson VW; Muss HB
Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
[TBL] [Abstract][Full Text] [Related]
35. Acute effects of combined photodynamic therapy and hyperbaric oxygenation in lung cancer--a clinical pilot study.
Tomaselli F; Maier A; Sankin O; Anegg U; Stranzl U; Pinter H; Kapp K; Smolle-Jüttner FM
Lasers Surg Med; 2001; 28(5):399-403. PubMed ID: 11413551
[TBL] [Abstract][Full Text] [Related]
36. The effect of intravenous infusion of Corynebacterium parvum on an immune profile of women with breast cancer.
Webster DJ; Chare MJ; Baum M
Dev Biol Stand; 1977 Apr 13-15; 38():467-70. PubMed ID: 608540
[TBL] [Abstract][Full Text] [Related]
37. [Hematological observations in patients following immunostimulation through intrapleural application of Corynebacterium parvum].
Karrer K; Denck H; Pridun N
Acta Med Austriaca; 1979; 6(5):209-12. PubMed ID: 233458
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant immunotherapy for bronchogenic carcinoma: preliminary results.
Takita H; Brugarolas A
Cancer Chemother Rep 3; 1973 Mar; 4(2):293-8. PubMed ID: 4729333
[No Abstract] [Full Text] [Related]
39. In vitro and in vivo effects of Corynebacterium parvum on lymphocyte transformation.
Fisher RA
Dev Biol Stand; 1977 Apr 13-15; 38():461-6. PubMed ID: 608539
[TBL] [Abstract][Full Text] [Related]
40. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
